What is SLU-PP-332?
SLU-PP-332 is a synthetic compound developed at Saint Louis University that functions as a pan-agonist of estrogen-related receptors (ERRs), specifically targeting ERRa, ERRb, and ERRg with highest potency at ERRa. Estrogen-related receptors are nuclear transcription factors that regulate gene networks governing oxidative metabolism, mitochondrial biogenesis, and energy homeostasis. Because these pathways are also activated by endurance exercise, SLU-PP-332 is classified as an exercise mimetic: a compound that reproduces cellular adaptations associated with aerobic physical activity through pharmacological means rather than mechanical work.
The molecular mechanism centers on ERRa's control of the DDIT4 (DNA damage-inducible transcript 4) pathway. Research published in ACS Chemical Biology (2022) demonstrated that SLU-PP-332 treatment induces DDIT4 expression specifically through ERRa activation, recapitulating a key genetic response observed after short bouts of aerobic exercise in humans. Downstream of this activation, genes encoding proteins involved in fatty acid oxidation, oxidative phosphorylation, and mitochondrial function are upregulated in skeletal muscle cells, producing a metabolic state resembling aerobic-trained muscle. This mechanism is distinct from REV-ERB agonists like SR-9011 or PPAR delta agonists like GW501516; ERR agonists occupy a unique node in the exercise-responsive transcriptional network.
In animal studies, SLU-PP-332 produced measurable gains in exercise endurance. Mice treated with the compound and placed on running protocols showed 20 to 30% improvements in running distance and time compared to vehicle-treated controls, along with increased proportions of type IIa oxidative muscle fibers, which are associated with sustained aerobic effort. Whole-body metabolic studies showed increased energy expenditure and enhanced fatty acid oxidation, accompanied by reduced fat mass accumulation over time without changes in food intake. A 2023 study published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that ERRa agonism with SLU-PP-332 effectively reduced obesity and improved insulin sensitivity in murine models of metabolic syndrome.
The research interest in SLU-PP-332 extends to its potential role in aging, sarcopenia, and conditions where exercise capacity is limited by disease or disability. The ability to pharmacologically engage aerobic exercise gene programs could theoretically benefit patients with heart failure, COPD, mobility limitations, or severe obesity who cannot engage in sufficient physical activity. No human clinical trials have been initiated as of early 2026, and all efficacy and safety data are preclinical.
Research Supply
Source high-purity SLU-PP-332 for your research
Dosage Guide
Route: Intraperitoneal in published murine studies; oral bioavailability under investigation; no validated human protocol
Dosing Schedule
| Period | Dose |
|---|---|
| Animal studies | Varied intraperitoneal dosing; specific mg/kg protocols vary by study |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|
Administration Tips
- No established human dosing protocol exists; all data are preclinical
- Pharmacokinetic data in humans are unavailable; animal studies suggest moderate clearance
- Frequency and duration of dosing for sustained ERR activation in humans have not been characterized
- For laboratory use, typically dissolved in DMSO for stock preparation
- Human bioavailability and safe dose ranges remain unknown
Risks & Side Effects
Commonly Reported
Serious Risks
No chronic toxicology data
No chronic toxicology data exist in any species beyond rodents. Long-term safety in humans is entirely unknown.
Off-target ERR effects
ERR receptors are expressed in numerous tissue types including heart, brain, kidney, and liver. Systemic ERR agonism may produce off-target effects not yet characterized.
Potential oncological risk
ERRa interacts with pathways involved in breast and other cancer cell proliferation. The implications of pan-ERR agonism for oncological risk are unknown and are an active area of investigation.
Immunological effects
ERR receptors modulate immune cell function. Chronic activation may alter immune surveillance in ways not yet characterized.
Contraindications
- Do not use in pregnancy or breastfeeding
- Avoid in individuals with active or prior hormone-sensitive cancers
- Avoid concurrent use with other nuclear receptor-targeting compounds without expert oversight
- Not appropriate for pediatric use
Frequently Asked Questions
Related Peptides
Experts Covering SLU-PP-332
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. SLU-PP-332 has not been approved by the FDA for any medical condition and is classified as a research compound only. No human clinical trial data exist for SLU-PP-332. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.